Article
|
Open Access
Featured
-
-
Article
| Open Access
AI is a viable alternative to high throughput screening: a 318-target study
- Izhar Wallach
- , Denzil Bernard
- & Abraham Heifets
-
Article
| Open Access
Novel antimicrobial peptides against Cutibacterium acnes designed by deep learning
- Qichang Dong
- , Shaohua Wang
- & Lun Yu
-
Article
| Open Access
Structure-based discovery of novel P-glycoprotein inhibitors targeting the nucleotide binding domains
- Laust Moesgaard
- , Maria L. Pedersen
- & Jacob Kongsted
-
Article
| Open Access
Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies
- Mohammed Alrouji
- , Lizy Sonia Benjamin
- & Atiya Akhtar
-
Article
| Open Access
Identification of potential new COVID-19 treatments via RWD-driven drug repurposing
- Yun Liao
-
Article
| Open Access
A multi-targeted computational drug discovery approach for repurposing tetracyclines against monkeypox virus
- Thamir A. Alandijany
- , Mai M. El-Daly
- & Esam I. Azhar
-
Article
| Open Access
An interaction-based drug discovery screen explains known SARS-CoV-2 inhibitors and predicts new compound scaffolds
- Philipp Schake
- , Klevia Dishnica
- & Michael Schroeder
-
Article
| Open Access
Scaffold repositioning of spiro-acridine derivatives as fungi chitinase inhibitor by target fishing and in vitro studies
- Jéssika de Oliveira Viana
- , Eden Silva e Souza
- & Euzébio Guimarães Barbosa
-
Article
| Open Access
MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference
- Olanrewaju Ayodeji Durojaye
- , Nkwachukwu Oziamara Okoro
- & Bennett Chima Nwanguma
-
Article
| Open Access
Fast calculation of hydrogen-bond strengths and free energy of hydration of small molecules
- Gian Marco Ghiandoni
- & Eike Caldeweyher
-
Article
| Open Access
In silico assessment on TdP risks of drug combinations under CiPA paradigm
- Ali Ikhsanul Qauli
- , Aroli Marcellinus
- & Ki Moo Lim
-
Article
| Open Access
Virtual screening and molecular dynamics simulations provide insight into repurposing drugs against SARS-CoV-2 variants Spike protein/ACE2 interface
- Davide Pirolli
- , Benedetta Righino
- & Maria Cristina De Rosa
-
Article
| Open Access
Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy
- Francesca Margara
- , Yiangos Psaras
- & Alfonso Bueno-Orovio
-
Article
| Open Access
The use of machine learning modeling, virtual screening, molecular docking, and molecular dynamics simulations to identify potential VEGFR2 kinase inhibitors
- Abbas Salimi
- , Jong Hyeon Lim
- & Jin Yong Lee
-
Article
| Open Access
Reduction of stress responses in honey bees by synthetic ligands targeting an allatostatin receptor
- Adrià Sánchez-Morales
- , Véronique Gigoux
- & Jean-Marc Devaud
-
Article
| Open Access
Absolute binding free energy calculations improve enrichment of actives in virtual compound screening
- Mudong Feng
- , Germano Heinzelmann
- & Michael K. Gilson
-
Article
| Open Access
Targeting SARS-CoV-2 endoribonuclease: a structure-based virtual screening supported by in vitro analysis
- Ibrahim M. Ibrahim
- , Abdo A. Elfiky
- & Mahmoud ElHefnawi
-
Article
| Open Access
(+)-Usnic acid and its salts, inhibitors of SARS‐CoV‐2, identified by using in silico methods and in vitro assay
- Eunseok Oh
- , Weihong Wang
- & Heonjoong Kang
-
Article
| Open Access
Inhibition of the hexamerization of SARS-CoV-2 endoribonuclease and modeling of RNA structures bound to the hexamer
- Duy Phuoc Tran
- , Yuta Taira
- & Akio Kitao
-
Article
| Open Access
GLUT3 inhibitor discovery through in silico ligand screening and in vivo validation in eukaryotic expression systems
- Cristina V. Iancu
- , Giovanni Bocci
- & Jun-yong Choe
-
Article
| Open Access
Determination of tyrosinase-cyanidin-3-O-glucoside and (−/+)-catechin binding modes reveal mechanistic differences in tyrosinase inhibition
- Kyung Eun Lee
- , Shiv Bharadwaj
- & Sang Gu Kang
-
Article
| Open Access
Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence
- Kanglin Hsieh
- , Yinyin Wang
- & Yejin Kim
-
Article
| Open Access
A computational study of cooperative binding to multiple SARS-CoV-2 proteins
- Jianing Li
- , Kyle T. McKay
- & Severin T. Schneebeli
-
Article
| Open Access
Identification of new GLUT2-selective inhibitors through in silico ligand screening and validation in eukaryotic expression systems
- Sina Schmidl
- , Oleg Ursu
- & Jun-yong Choe
-
Article
| Open Access
Combination of consensus and ensemble docking strategies for the discovery of human dihydroorotate dehydrogenase inhibitors
- Garri Chilingaryan
- , Narek Abelyan
- & Hovakim Zakaryan
-
Article
| Open Access
In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer
- Z. Ping Lin
- , Nour N. Al Zouabi
- & Elena S. Ratner
-
Article
| Open Access
Potential repurposing of four FDA approved compounds with antiplasmodial activity identified through proteome scale computational drug discovery and in vitro assay
- Bakary N’tji Diallo
- , Tarryn Swart
- & Kevin Lobb
-
Article
| Open Access
Virtual screening of anti-HIV1 compounds against SARS-CoV-2: machine learning modeling, chemoinformatics and molecular dynamics simulation based analysis
- Mahesha Nand
- , Priyanka Maiti
- & Muthannan Andavar Ramakrishnan
-
Article
| Open Access
Ensemble transfer learning for the prediction of anti-cancer drug response
- Yitan Zhu
- , Thomas Brettin
- & Rick L. Stevens
-
Article
| Open Access
Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches
- John F. Darby
- , Lewis R. Vidler
- & Paul Workman
-
Article
| Open Access
Virtual screening identifies broad-spectrum β-lactamase inhibitors with activity on clinically relevant serine- and metallo-carbapenemases
- Francesca Spyrakis
- , Matteo Santucci
- & Maria Paola Costi
-
Article
| Open Access
A site-moiety map and virtual screening approach for discovery of novel 5-LOX inhibitors
- Kai-Cheng Hsu
- , Wei-Chun HuangFu
- & Jinn-Moon Yang
-
Article
| Open Access
Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancer
- Anton Cheltsov
- , Natsuko Nomura
- & Elmar Nurmemmedov
-
Article
| Open Access
Development of an in silico prediction system of human renal excretion and clearance from chemical structure information incorporating fraction unbound in plasma as a descriptor
- Reiko Watanabe
- , Rikiya Ohashi
- & Kenji Mizuguchi
-
Article
| Open Access
Discovery of Novel Multi-target Inhibitor of angiotensin type 1 receptor and neprilysin inhibitors from Traditional Chinese Medicine
- Xiaoqian Huo
- , Liansheng Qiao
- & Yanling Zhang
-
Article
| Open Access
Novel application of neural network modelling for multicomponent herbal medicine optimization
- Yong-Shen Ren
- , Lei Lei
- & Zhi-Nan Mei
-
Article
| Open Access
Fragment-based discovery of the first nonpeptidyl inhibitor of an S46 family peptidase
- Yasumitsu Sakamoto
- , Yoshiyuki Suzuki
- & Nobutada Tanaka
-
Article
| Open Access
Rational design using sequence information only produces a peptide that binds to the intrinsically disordered region of p53
- Kiyoto Kamagata
- , Eriko Mano
- & Tomoshi Kameda
-
Article
| Open Access
In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors
- Muhammad Usman Mirza
- , Michiel Vanmeert
- & Muhammad Idrees
-
Article
| Open Access
Application of ESMACS binding free energy protocols to diverse datasets: Bromodomain-containing protein 4
- David W. Wright
- , Shunzhou Wan
- & Peter V. Coveney
-
Article
| Open Access
Identification of Allosteric Inhibitors against Active Caspase-6
- Agne Tubeleviciute-Aydin
- , Alexandre Beautrait
- & Andrea C. LeBlanc
-
Article
| Open Access
Hybrid approach to sieve out natural compounds against dual targets in Alzheimer’s Disease
- Sucharita Das
- , Sandipan Chakraborty
- & Soumalee Basu
-
Article
| Open Access
Merits and pitfalls of conventional and covalent docking in identifying new hydroxyl aryl aldehyde like compounds as human IRE1 inhibitors
- Antonio Carlesso
- , Chetan Chintha
- & Leif A. Eriksson
-
Article
| Open Access
The impact of estimated tumour purity on gene expression-based drug repositioning of Clear Cell Renal Cell Carcinoma samples
- Karel K. M. Koudijs
- , Anton G. T. Terwisscha van Scheltinga
- & Henk-Jan Guchelaar
-
Article
| Open Access
Macrophage Migration Inhibitory Factor Acts as the Potential Target of a Newly Synthesized Compound, 1-(9′-methyl-3′-carbazole)-3, 4-dihydro-β-carboline
- Pin-Hao Ko
- , Ya-Ching Shen
- & Liang-Chuan Lai
-
Article
| Open Access
Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus
- Muhammad Tahir ul Qamar
- , Arooma Maryam
- & Abdul Rauf Siddiqi
-
Article
| Open Access
OptiPharm: An evolutionary algorithm to compare shape similarity
- S. Puertas-Martín
- , J. L. Redondo
- & H. Pérez-Sánchez
-
Article
| Open Access
Discovering highly selective and diverse PPAR-delta agonists by ligand based machine learning and structural modeling
- Benny Da’adoosh
- , David Marcus
- & Amiram Goldblum
-
Article
| Open Access
Silibinin, A Natural Blend In Polytherapy Formulation For Targeting Cd44v6 Expressing Colon Cancer Stem Cells
- Shanaya Patel
- , Bhargav Waghela
- & Rakesh Rawal
Inferring molecular inhibition potency with AlphaFold predicted structures